Cerveau Technologies announces research collaboration agreement with Janssen Pharmaceuticals

Oct 16 (Reuters) - Cerveau Technologies Inc:
* Says announced a research collaboration agreement with Janssen Pharmaceuticals Inc for use of MK-6240​ ‍​
* Says collaboration is focused on using MK-6240 as a biomarker in Janssen neurodegenerative disease research studies​
* Says parties will collaborate on using MK-6240 to diagnose and evaluate new treatments for neurodegenerative diseases in humans​ Source text for Eikon: Further company coverage:

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Purchase Licensing Rights